NCT06307223View on ClinicalTrials.gov

Efficacy and Safety of 30% Supramolecular Salicylic Acid Combined With Supramolecular Active Zinc in the Treatment of Malassezia Folliculitis

PHASE4CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

June 7, 2022

Primary Completion Date

September 20, 2023

Study Completion Date

September 20, 2023

Conditions
Malassezia Folliculitis
Interventions
DRUG

30% supramolecular salicylic acid

The patients received weekly application of 30% supramolecular salicylic acid for a duration of 8 weeks.

DRUG

supramolecular active zinc

The patients received daily application of topical supramolecular active zinc anti-dandruff lotion for a duration of 8 weeks.

Trial Locations (1)

710000

The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an

All Listed Sponsors
lead

Second Affiliated Hospital of Xi'an Jiaotong University

OTHER